Familial hypercholesterolemia: diagnosis, genetic aspects, and current treatment approaches
Bulletin of the Russian Military Medical Academy · 27.03.2026 · 28 (1) · 129-136
DOI: 10.17816/brmma682901 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin of the Russian Military Medical Academy, online erschienen am 27.03.2026. Verfasst von Makar A. Bazhin und 4 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Familial hypercholesterolemia is an inherited disorder of lipoprotein metabolism characterized by persistently elevated in low-density lipoprotein cholesterol levels, which substantially increases the risk of cardiovascular disease. Current diagnostic approaches include clinical criteria (family history and elevated cholesterol levels) and genetic testing, enabling earlier and more accurate identification of familial hypercholesterolemia in the early stages of the disease. There are various forms of inheritance patterns of familial hypercholesterolemia, including heterozygous and homozygous types, each with distinct genetic causes and risks of developing cardiovascular complications. The main diagnostic methods for familial hypercholesterolemia include: classical laboratory tests (lipid profile, complete blood count, blood biochemistry including glucose, creatinine, urea, total bilirubin, alanine aminotransferase, aspartate aminotransferase, and creatine phosphokinase), instrumental examinations (computed tomography and coronary angiography, duplex scanning of the extracranial brachiocephalic arteries, computed tomography for calcium score, and echocardiography), and genetic methods (polymerase chain reaction [PCR], expression of regulatory micro microRNAs, and DNA melting curve analysis). Screening programs, including cascade and targeted approaches, are key to early diagnosis and intervention, substantially improving the prognosis for patients with familial hypercholesterolemia. For example, implementing PCR testing in familial hypercholesterolemia screening enables assessment of the genetic mutation spectrum and refines the choice of lipid-lowering therapy. All this minimizes adverse reactions, as targeted therapy rapidly reduces cholesterol and low-density lipoprotein cholesterol to target levels, thereby preventing associated diseases and improving the patient's quality of life.
Zitieren
APA
Bazhin, M. A., Sveklina, T. S., Krutikova, A. A., Strelkov, D. A., & Bessonov, E. Y. (2026). Familial hypercholesterolemia: diagnosis, genetic aspects, and current treatment approaches. Bulletin of the Russian Military Medical Academy, 28(1), 129-136. https://doi.org/10.17816/brmma682901
Vancouver
Bazhin MA, Sveklina TS, Krutikova AA, Strelkov DA, Bessonov EY. Familial hypercholesterolemia: diagnosis, genetic aspects, and current treatment approaches. Bulletin of the Russian Military Medical Academy. 2026;28(1):129-136. doi:10.17816/brmma682901
BibTeX
@article{Bazhin2026,
author = {Bazhin, Makar A. and Sveklina, Tatyana S. and Krutikova, Anna A. and Strelkov, Dmitriy A. and Bessonov, Evgeny Yu.},
title = {Familial hypercholesterolemia: diagnosis, genetic aspects, and current treatment approaches},
journal = {Bulletin of the Russian Military Medical Academy},
year = {2026},
volume = {28},
number = {1},
pages = {129--136},
doi = {10.17816/brmma682901}
}
EUVIMED